Health
Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit – News-Medical.Net
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response…
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.
The phase III…
Continue Reading
-
Noosa News12 hours agoConsolidated Pastoral Company buys Beetaloo aggregation in historic deal worth more than $300m
-
General20 hours agoWotjobaluk Nations Festival marks landmark native title recognition
-
General14 hours agoAustralian luger Alex Ferlazzo makes stunning recovery during run after falling off his sled
-
Business24 hours agoWhat Warren Buffett’s latest portfolio moves say about the market